Search

Displaying results 681 - 690 of 7687 in total
  1. Drug

    Varenicline

    go.drugbank.com/drugs/DB01273
    ApprovedInvestigational

    The FDA said it is keeping the black box in place at least until the results of the trial are announced. … Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015.

    Mixtures: Nra-varenicline, Nra-vareniclineProducts: Nra-varenicline
  2. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    [L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test. … Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022.

  3. Drug

    Copper oxodotreotide Cu-64

    go.drugbank.com/drugs/DB15873
    Approved

    [A220348] Copper Cu 64 dotatate has a longer half-life and can be produced once a day as opposed to several times a day, and lower positron energy lending to improved spatial resolution. … Copper Cu 64 dotatate is a newly approved Cu labeled somatostatin analog and has several advantages over <sup>68</sup>Ga-labeled somatostatin analogs for positron emission tomography (PET).

    Synonyms: Copper Cu-64 dotatate, Copper dotatate Cu-64
  4. Drug

    Aripiprazole lauroxil

    go.drugbank.com/drugs/DB14185
    Approved

    It is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors [A34289]. … pathway activating D2 receptors, whereas negative symptoms may result from a decreased activity in the mesocortical dopaminergic pathway with D1 receptors predominating [T28].

  5. Drug

    Pemigatinib

    go.drugbank.com/drugs/DB15102
    ApprovedInvestigational

    growth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test. … [A198963] The FDA-approved indication for pemigatinib was granted under accelerated approval based on the overall response rate and duration of response in pre-marketing clinical trials.

  6. Drug

    Pentetic acid

    go.drugbank.com/drugs/DB14007
    ApprovedInvestigational

    [L2242] DPTA was developed by the pharmaceutical company CIS US and FDA approved on April 14, 2004.[L1469] … Pentetic acid, also known as diethylenetriaminepentaacetic acid (DTPA), is a synthetic polyamino carboxylic acid with eight coordinate bond forming sites that can sequester metal ions and form highly stable

  7. Drug

    Rotavirus vaccine

    go.drugbank.com/drugs/DB10276
    ApprovedInvestigational

    Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rot...

  8. Drug

    Delafloxacin

    go.drugbank.com/drugs/DB11943
    ApprovedInvestigational

    Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, a...

  9. Drug

    Iopodic acid

    go.drugbank.com/drugs/DB09333
    ApprovedWithdrawn

    [A32080] Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was developed and filed to the FDA by the company BRACCO. … This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada.

  10. Drug

    Homatropine

    go.drugbank.com/drugs/DB11181
    Approved

    Homatropine is an anticholinergic drug that acts as an antagonist at muscarinic acetylcholine receptors. … administered as ophthalmic solutions as a cycloplegic to temporarily paralyze accomodation, and to induce mydriasis (the dilation of the pupil); however such therapeutic use has not been approved by the FDA